YS Biopharma granted additional 180 day extension by Nasdaq to regain compliance

YS Biopharma received an extension of 180 calendar days from to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement for continued listing following the expiration of the initial 180 calendar days period to regain compliance on April 22. Pursuant to the Extension Notice, the Company is eligible for an additional 180 calendar day period, or until October 21, to regain compliance with the Bid Price Requirement. In the event that the compliance cannot be demonstrated by October 25, the staff of Nasdaq will provide written notification that the company’s securities will be delisted. The company is considering its options in order to regain compliance with the Bid Price Requirement. The Extension Notice does not affect the Company’s business operations, its SEC reporting requirements, or its contractual obligations.